Scale -


  • Ebitda is 70.07 Rs Cr; Annual Growth is 18 %; Continuous Growth over 3 years; 5 Year CAGR is 25 %
  • Revenue is 287 Rs Cr; Continuous Growth over 3 years
  • PBT is 17.68 Rs Cr; 5 Year CAGR is 20 %; Annual Decline is -18 %
  • PAT is 43.08 Rs Cr; 5 Year CAGR is 22 %; Annual Decline is -22 %

Profitability -


  • PBDIT Margin is 24.39 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 17 %
  • PAT Margin is 14.99 %; in Top Quartile; 5 Year CAGR is 15 %; Annual Decline is -27 %
  • Quarterly Ebitda Margin is 21 %; in Top Quartile
  • Quarterly Profit margin is 16 %; in Top Quartile

Return -


  • ROCE is 21.02 %; Continuous Growth over 3 years; in Top Quartile
  • ROA is 13.6 %; in Top Quartile; Annual Decline is -32 %
  • ROE is 15.68 %; in Top Quartile; Annual Decline is -32 %
  • Asset Turnover is 97 %; in Top Quartile

Efficiency -


  • Inventory Turnover Ratio is 19.25; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 94 %
  • Current Ratio is 5.06; in Top Quartile; Continuous Decline over 3 years
  • Quick Ratio is 4.54; in Top Quartile; Continuous Decline over 3 years
  • Operating cash flow is 46.81 Rs Cr; 5 Year CAGR is 70 %

Solvancy -


  • Debt/Equity is 0; in Bottom Quartile
  • Total Debt is 0 Rs Cr; in Bottom Quartile
  • Contingent Liabilities is 22.34 Rs Cr; Annual Growth is 45 %; Continuous Growth over 3 years; 5 Year CAGR is 40 %

Quality -


  • Exceptional Items/PBT is -4 %; Annual Decline is -113 %; in Bottom Quartile
  • Other Expenses/Total Expenses is 23 %; Continuous Decline over 3 years
  • Operating cashflow/ebitda is 67 %; 5 Year CAGR is 37 %; Annual Decline is -28 %; Continuous Decline over 3 years
  • Operating cashflow/PAT is 109 %; 5 Year CAGR is 40 %
  • Current Tax/PAT is 31 %; Annual Growth is 25 %
  • Change in Inventories/Total Expenses is 0 %; Annual Growth is 59 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Earnings call transcript: Jagsonpal Q2 2026 growth solid but shares fall 4.4% By Investing.com
Jagsonpal Pharmaceuticals’ Q2 FY27 Consolidated Revenue Rises 29% To ?964 Crore
Jagsonpal Q2 FY27 slides: building platform for acceleration By Investing.com
ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio